BTCC
/
BTCC Square
/
Global Cryptocurrency
/
C4 Therapeutics Stock Surges 34% on Analyst Upgrade and Pipeline Progress
C4 Therapeutics Stock Surges 34% on Analyst Upgrade and Pipeline Progress
7
3
BTCCSquare news:
C4 Therapeutics (CCCC) soared 34% Monday, outpacing both healthcare peers and broader markets after Stephens analyst Sudan Loganathan upgraded the stock to overweight. His new $6 price target implies nearly 100% upside from current levels.
The bullish reversal stems from promising developments in C4's multiple myeloma drug pipeline, particularly investigational therapy cemsidomide. Loganathan highlighted untapped potential in this blood cancer treatment market and emphasized the value of C4's strategic partnerships.
Investor attention now shifts to September 20, when the company will present phase 1 data at the International Myeloma Society meeting. This catalyst could further validate Loganathan's thesis about C4's growth trajectory.
By:
